Metformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: a non-randomized, pair-matched cohort study by Dai-Yin Lu et al.
Lu et al. BMC Cardiovascular Disorders 2014, 14:187
http://www.biomedcentral.com/1471-2261/14/187RESEARCH ARTICLE Open AccessMetformin use in patients with type 2 diabetes
mellitus is associated with reduced risk of deep
vein thrombosis: a non-randomized, pair-matched
cohort study
Dai-Yin Lu1, Chin-Chou Huang1,2,3,4, Po-Hsun Huang1,3,5, Chia-Min Chung6, Shing-Jong Lin1,2,3,5,
Jaw-Wen Chen1,2,3,5, Wan-Leong Chan1,7 and Hsin-Bang Leu1,2,3,5,7*Abstract
Background: Metformin, an insulin-sensitizer, may correct several physiologic abnormalities owing to insulin resistance
in patients with type 2 diabetes mellitus (DM). The effects of metformin on venous thrombosis in patient with type 2
DM have not been reported. Our study strived to explore the relationship of metformin therapy and the subsequent
development of deep vein thrombosis (DVT) using a nationwide, population-based database.
Methods: From 1997 to 2003, we identified a study cohort consisting of patients with type 2 DM using metformin
7154 cases in the National Health Insurance Research Database. A control cohort without metformin, matched for age,
sex, comorbidities, and medications was selected for comparison.
Results: Of the 14945 patients (7167 patients with metformin vs. 7778 control), 60 (0.40%) patients developed DVT
during a mean follow-up period of 3.74 years, including 16 (0.21%) from the cohort with metformin and 44 (0.56%)
from the control group. Subjects with metformin experienced a 0.427 fold (95% confidence interval 0.240-0.758;
P = 0.004) changes of risk reduction in development of DVT, which was independent of age, sex and co-morbidities.
Kaplan-Meier analysis also revealed metformin therapy is associated with lower occurrence of DVT (log-rank test,
P = 0.001).
Conclusions: Metformin may have protective effect in patients with type 2 DM for DVT.
Keywords: Deep vein thrombosis, Metformin, Type 2 diabetes mellitusBackground
Vascular disease is a major cause of morbidity and mor-
tality among patients with diabetes, and these patients
account for a significant proportion of all patients with
cardiovascular disease, including coronary artery disease,
acute myocardial infarction, and cerebral infarction [1].
Insulin resistance contributes greatly to development of
cardiovascular disease in patient with metabolic syn-
drome and type 2 diabetes mellitus (DM). Therefore,
treatment with an insulin-sensitizing agent, such as* Correspondence: hbleu@vghtpe.gov.tw
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unless otherwise stated.metformin may correct several of the primary patho-
physiologic abnormalities, including lipid metabolism,
endothelial function, and platelet hyperactivity in pa-
tients with diabetes mellitus [2]. The United Kingdom
Prospective Diabetes Study Group (UKPDS) has shown
that patients with type 2 DM treated with metformin
had a 36% lower risk of all-cause mortality and 39%
lower risk of myocardial infarction respectively com-
pared with those treated conventionally. This risk reduc-
tion was especially greater for metformin than insulin or
sulphonylurea treatment, despite similar glycemic con-
trol [3]. Metformin appears to provide cardiovascular
protection beyond blood sugar control. In addition to
arterial vascular disease, pathology on venous system is
also common in patients with diabetes. Epidemiologicalis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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thrombosis and pulmonary embolism among diabetic
patients [4,5]. Deep venous thrombosis frequently causes
limitation on daily activities, while pulmonary embolism
may further contribute to a life-threatening condition.
The effects of metformin on venous thrombosis in pa-
tient with type 2 diabetes have not been previously re-
ported. We hypothesized that metformin may reduce
the development of venous thrombosis in patient with
type 2 diabetes. Utilizing a nationwide database, we
conducted this nonrandomized, pair-matched cohort
study to investigate the relationship between metformin
therapy and the subsequent development of deep venous
thrombosis among patients with type 2 diabetes mellitus.
Methods
Database
The National Health Insurance program in Taiwan has
been operating since 1995 and has enrolled nearly all the
inhabitants of Taiwan (23,074,487 beneficiaries out of
23,162,123 inhabitants at the end of 2010). The National
Health Insurance Research Database (NHIRD) at the
National Health Research Institutes (NHRI) (http://w3.
nhri.org.tw/nhird/en/index.htm) in Miao-Li (Taiwan) is
in charge of the entire National Health Insurance claims
database, and it has published numerous extracted
datasets for researchers. The NHRI released a cohort
dataset comprising 1,000,000 randomly sampled people
who were alive during 1997 and collected all the records
of these individuals from 1995 onwards. The database
has been confirmed by NHRI to be representative of the
Taiwanese population [6]. It is also one of the largest
nationwide population-based databases in the world,
with more than 1000 scientific articles published using
its data [7]. In this cohort dataset, each patient’s original
identification number has been encrypted to protect
privacy. Of note, the encrypting procedure is consistent
such that the linkage of claims belonging to the same
patient is feasible within the NHIRD datasets. The current
study was conducted using HNIRD dataset which con-
tained patients’ all medical claim records, including
coverage for outpatient, inpatient, emergency, dental,
traditional Chinese medicine services, and prescription
drugs. Because the NHIRD consists of de-identified sec-
ondary data released to the public for research purposes,
this study was exempt from full review by the Institutional
Review Board. The encrypting procedure is consistent, so
the linkage of claims belonging to the same patient is feas-
ible within the NHIRD.
Study sample and control
We identified patients who used metformin for dia-
betes treatment (International Classification of Diseases,
Ninth Revision, Clinical Modification [ICD-9-CM] codes250.0 - 250.9) from the 1,000,000 sampling cohort dataset
from January 1, 1997. An age-, sex-, and co-morbidity
matched non-expose control group was selected from
those patients who did not use metformin throughout the
whole course of follow-up. To investigate the causal rela-
tionship between metformin use and deep venous throm-
bosis (DVT) occurrence, in both groups, subjects with
pre-existing DVT (ICD-9-CM codes 453.0-453.9) before
enrollment were excluded from this study. Women with
diagnosis of pregnancy during study period were also
excluded, since the first-line anti-hyperglycemic agent for
gestational diabetes is insulin, not metformin [8]. The
co-morbidities to be matched in the 2 groups included
pre-existing (upon enrollment) hypertension (ICD-9-CM
codes 401.xx–405.xx), coronary artery disease (CAD)
(411.xx, 413.xx, 414.xx), hyperlipidemia (272–272.4).
Previously well documented risk factors for DVT were
recorded, such as cancer (140.xx-199.1), traumatic or
pathologic fractures involving spine, pelvis, upper, and
lower limbs (733.10-733.19, 800.xx-829.xx), and major
cardiothoracic, abdominal, pelvic surgeries and ortho-
pedic surgeries of lower limbs. Concurrent medica-
tions for blood sugar control, statin, anti-platelet, anti-
coagulant agents or hormone replacement therapy
were also recorded in our study.
Deep vein thrombosis event measurement
The end point of the study was defined as occurrence of
DVT (ICD-9-CM codes 453.0-453.9). In this database,
the ICD codes of DVT and the drug code of metformin
did not change throughout the whole follow-up period
(1997–2003), assuring the consistency of the disease and
medication registry. Similar coding to identify DVT
events has also been also used in our previous study [9].
Statistical analysis
Microsoft SQL Server 2005 (Microsoft Corporation,
Redmond, Wash) was used for data management and
computing. Statistical analyses were performed utilizing
SPSS software (Version 18.0; SPSS, Inc., Chicago, Ill). All
data were expressed as mean ± SD or percentage. Com-
parisons between the 2 groups were determined by inde-
pendent Student’s t test for continuous variables or
Pearson’s 2 test, Yates’ correction for continuity/Fisher’s
exact test as appropriate for categorical variables. Sur-
vival analysis also was assessed using the Kaplan-Meier
method, with the significance based on the log-rank test.
Cox proportional hazards models were used to test the
association of metformin use with DVT. Statistical sig-
nificance was inferred at a 2-sided P value of <0.05.
Results
A total of 7167 type 2 DM patients who used metformin
(mean age 57.70 ± 12.55 years) were identified from the
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and December 2003. Another 7778 subjects without
metformin therapy (mean age 57.72 ± 13.37 years) were
matched for age, sex, co-morbidities, medications, serv-
ing as the control group. The demographic parameters
of study subjects are listed in Table 1. Figure 1 showed
the entire flow of study and most enrollees in both
groups (88.1% in metformin cohort and 88.6% in the
control group) remained active and were followed
through the end of the study at the end of the study
period (December 31, 2003).
During an average of 3.74 ± 0.80 years’ follow-up
period, there was a significantly lower incidence of DVT
development among patients with type 2 diabetes who
used metformin, compared with the control group (16
[0.22%] vs 44 [0.56%], P < 0.001). Figure 2 outlines the
results of a Kaplan-Meier analysis and the log-rank test,







Age, years 57.72 ± 13.37 57.70 ± 12.55 0.937
Male gender 4095 (52.6) 3808 (53.1) 0.565
Hypertension 1885 (24.2) 1695 (23.7) 0.413
CAD 671 (8.6) 535 (7.5) 0.010
Hyperlipidemia 905 (11.6) 849 (11.8) 0.708
Atrial fibrillation 69 (0.9) 35 (0.5) 0.005
Cancer 372 (3.8) 308 (4.3) 0.155
Fracture 538 (6.9) 364 (5.1) <0.001
Major surgery 405 (5.2) 321 (4.5) 0.04
Medications
Aspirin 696 (8.9) 692 (9.7) 0.144
Clopidogrel 12 (0.2) 8 (0.1) 0.625
Warfarin 31 (0.4) 36 (0.5) 0.409
Statin 263 (3.4) 342 (4.8) <0.001
HRT 45 (0.6) 54 (0.8) 0.203
Other anti-hyperglycemic agents
SU 7652 (98.4) 6941 (96.8) <0.001
Meglitinide 2117 (27.2) 626 (8.7) <0.001
α-glucosidase Inhibitor 2629 (33.8) 938 (13.1) <0.001
TZD 2663 (34.2) 1188 (16.6) <0.001
Insulin 5377 (69.1) 2342 (32.7) <0.001
Kind of drug used 2.63 ± 0.84 2.68 ± 0.85 <0.001
Data are the mean ± SD and n (%).
CAD indicates coronary artery disease; HRT, hormone replacement therapy;
SU, sulfonylurea; TZD, Thiazolidinediones.
Fracture includes traumatic or pathological fracture involving upper or lower
limbs, spine and pelvis.
Major surgery includes cardiothoracic, abdominal, pelvic surgery or orthopedic
surgery of lower limbs.with a significantly lower incidence of DVT than those
without metformin (Log-rank P = 0.001). The significant
difference between groups was observed in the first year,
even just after six months treatment of metformin.
Comparison between patients with and without DVT
was shown in Table 2. Patients with DVT were older,
more likely to be male, with more co-morbidities of
coronary artery disease, fractures and performed more
major surgeries.
The Cox proportional hazards regression model was
used to determine the factors independently associated
with the development of DVT. After adjusting for age,
sex, and the aforementioned significant co-morbidities,
only age (hazard ratio [HR] 1.031; 95% CI, 1.009-1.053);
P = 0.004), CAD (HR 2.208; 95%, CI, 1.026-4.751;
P = 0.043), and major surgery ([HR] 3.161; 95% CI,
1.535-6.510; P = 0.002) were independently associated
with DVT development, while metformin was independ-
ently associated with lower risk of DVT (HR 0.427;
95%, CI, 0.240-0.758; P = 0.004) (Table 3).
Discussions
Our major findings of the present study demonstrated
metformin use was associated with reduced risk of de-
veloping DVT among patients with type 2 DM using a
large-scale nationwide database in Asian population. In
addition, increasing age and history of cardiovascular
disease were found to contribute independently to the
risk of DVT.
Metformin is an insulin-sensitizing biguanide used to
treat type 2 DM. The glucose-lowering effect is a conse-
quence of reduced hepatic gluconeogenesis and increased
insulin-stimulated glucose uptake in skeletal muscle and
adipocytes [10,11]. In addition to the anti-hyperglycemic
effects, metformin provides additional cardioprotective
effects beyond sugar lowering, which may be related to the
actions of metformin on lipid metabolism, vascular smooth
muscle and cardiomyocyte intracellular calcium handling,
endothelial function, hyper-coagulation and platelet hyper-
activity. It also provide greater protection against the devel-
opment of macrovascular complications than would be
expected from its effects on glycemic control alone [12].
There are statistically significant reductions in the risk
of all-cause mortality and diabetes-related mortality
[3]. Either as monotherapy or in combination with
sulfonylurea, metformin was associated with reduced
all-cause and cardiovascular mortality compared with
sulfonylurea monotherapy [13]. The UKPDS post-trial
reported significant and persistent risks reductions for
diabetes-related end point, myocardial infarction and
death from any cause [14]. Current guidelines from
the American Diabetes Association/European Association
for the study of Diabetes (ADA/EASD) recommend
early initiation of metformin as a first-line drug for
Figure 1 Study flow chart.
Table 2 Baseline characteristics of the DVT population
DVT
No (N = 14885) Yes (N = 60) P value
Age, years 57.69 ± 12.98 62.35 ± 13.31 0.006
Male gender 7867 (52.8) 36 (60) 0.328
Lu et al. BMC Cardiovascular Disorders 2014, 14:187 Page 4 of 7
http://www.biomedcentral.com/1471-2261/14/187monotherapy and for combination therapy for patients
with type 2 diabetes [15].
Our cohort study is the first study to document the
protective effect of metformin on venous thrombo-
embolism using a large-scale nationwide cohort data-
base. It is widely accepted that DM impairs endothelial
nitric oxide synthase (eNOS) activity and enhances
the production of reactive oxygen species (ROS), thusFigure 2 Kaplan-Meier curves revealed patient under metformin
therapy was associated with lower incidence of deep vein
thrombosis (log-rank test, p = 0.001).
Hypertension 3560 (23.9) 20 (33.3) 0.120
CAD 1194 (8.0) 12 (20) 0.003
Hyperlipidemia 1745 (11.7) 9 (15) 0.558
Atrial fibrillation 102 (0.7) 2 (3.3) 0.065
Cancer 674 (4.5) 680 (4.6) 0.054
Fracture 894 (6.0) 8 (13.3) 0.027
Major surgery 716 (4.8) 10 (16.7) 0.001
Medications
Aspirin 1381 (9.3) 7 (11.7) 0.679
Clopidogrel 20 (0.1) 0 (0.0) 1.000
Warfarin 63 (0.4) 4 (6.7) <0.001
Statin 601 (4.0) 4 (6.7) 0.308
HRT 99 (0.7) 0 (0.0) 1.000
Metformin 7151 (48.0) 16 (26.7) 0.001
Data are the mean ± SD and n (%).
CAD indicates coronary artery disease; HRT, hormone replacement therapy.
Fracture includes traumatic or pathological fracture involving upper or lower
limbs, spine and pelvis.
Major surgery includes cardiothoracic, abdominal, pelvic surgery or orthopedic
surgery of lower limbs.
Table 3 Predictors of deep vein thrombosis identified by
uni- and multi-variate Cox regression analysis
Univariate analysis Multi-variate analysis
HR (95% CI) P HR (95% CI) P
Age, per year 1.032 (1.010-1.054) 0.004 1.031 (1.009-1.053) 0.004
Male gender 1.361 (0.812-2.282) 0.242 1.577 (0.934-2.661) 0.088
Hypertension 1.611 (0.942-2.755) 0.082 1.007 (0.541-1.874) 0.983
CAD 2.956 (1.570-5.564) 0.001 2.208 (1.026-4.751) 0.043
Hyperlipidemia 1.290 (0.635-2.621) 0.481 0.921 (0.407-2.084) 0.844
Cancer 2.694 (1.159-6.263) 0.021 1.598 (0.657-3.888) 0.301
Fracture 2.495 (1.185-5.251) 0.016 1.918 (0.899-4.094) 0.092
Major surgery 4.055 (2.057-7.996) <0.001 3.161 (1.535-6.510) 0.002
Aspirin 1.315 (0.598-2.891) 0.496 0.703 (0.291-1.701) 0.435
Dipyridamole 1.014 (0.368-2.797) 0.978 0.728 (0.257-2.063) 0.550
Statin 1.667 (0.604-4.596) 0.324 1.553 (0.499-4.836) 0.448
Metformin 0.395 (0.223-0.700) 0.001 0.427 (0.240.0.758) 0.004
CAD indicates coronary artery disease.
Fracture includes traumatic or pathological fracture involving upper or lower
limbs, spine and pelvis.
Major surgery includes cardiothoracic, abdominal, pelvic surgery or orthopedic
surgery of lower limbs.
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sequent pro-atherogenetic alterations [16]. Insulin is a
normal regulator of eNOS activation and NO production
through successive phosphorylation. Insulin resistance in
DM attenuates the process and suppresses the normal
NO secretion [17]. In previous studies, metformin treat-
ment significantly improved glycation, oxidative stress,
nitric oxide (NO) bioavailability and insulin resistance
and normalized endothelial function in aorta of rats
with diabetes [18]. In human, subjects who received
metformin had improvement in endothelium-dependent,
acetylcholine-stimulated flows compared with those
treated with placebo. In young women with polycystic
ovary syndrome, which have an increased prevalence of
insulin resistance, short-term metformin therapy im-
proves arterial stiffness and endothelial function [19]. Al-
though the mechanism was still not clear, metformin
may help restore endothelial function via modulation of
insulin resistance.
It has been reported that metformin treatment was
associated with improvements in plasma markers of
endothelial function, including von Willebrand factor
(vWF), soluble vascular adhesion molecule-1 (sVCAM-1),
tissue-type plasminogen activator (t-PA), plasminogen
activator inhibitor-1 (PAI-1) and soluble intercellular
adhesion molecule-1 (sICAM-1), suggesting the benefit of
endothelial function improvement and inflammation re-
duction [20]. Metformin have specific effects on endothe-
lial function protection, which explained about 34% of the
reduction in the in the risk of CV morbidity and mortality
[20]. These findings indicate that metformin is able toimprove endothelial reactivity at the macro- and microcir-
culatory level, both of which relate to cardiovascular out-
comes [21,22].
Insulin resistance is associated with hypofibrinolysis,
and metformin has been shown to improve insulin sensi-
tivity and fibrinolysis [23]. In animal model, metformin
prolonged activated partial thromboplastin and pro-
thrombin times, and the endothelial cell damage im-
proved [24]. Sobel et al. demonstrated insulin-sensitizing
strategy led to lower fibrinogen level [25]. It may alter
fibrin structure and function by interfering with the
process involved in fibrin polymerization and lateral
aggregation [26]. A reduction in coagulation factor VII
levels and factor VIII activity had also been demon-
strated [26,27]. In subjects with obesity, there was a
significantly greater decrease in tissue plasminogen acti-
vator (t-PA) antigen and vWF in the metformin than in
the placebo group. The use of metformin increased t-PA
activity and decreased t-PA antigen in patients with
insulin resistance and hypertension [23,28]. Patients with
newly diagnosed type 2 diabetes treated with 8-week met-
formin received an intravenous infusion of L-arginine
before and after metformin treatment, while L-arginine is
the natural precursor of NO and may be useful to assess
endothelium-dependent vascular function in humans. The
decrease in both platelet aggregation and blood viscosity
after L-arginine was significantly amplified after metfor-
min [29]. Therefore insulin sensitizing therapy with met-
formin may alter the coagulation profiles, which bring
beneficial consequences in the thrombogenesis. Together
all, metformin may have better endothelial protection and
coagulation, which may provide possible mechanisms con-
nected to the reduced DVT events observed in our study.
A number of published studies have shown that the
incidence of first-time venous thromboembolism (VTE)
rises with age. The incidence increases dramatically after
age 60 [30,31]. Although use of oral contraceptives and
post-menopausal hormone replacement have been asso-
ciated with VTE in women, published data suggest no
consistent differences in the incidence of VTE among
men and women [31]. Besides, we demonstrated that
history of cardiovascular disease is associated with devel-
opment of DVT. In recent years, epidemiological studies
have explored the association between VTE, arterial
thromboembolism (CVD, MI, stroke) and atheroscler-
osis, indicating patients with DVT had an increased rela-
tive risk for MI and stroke [32]. Since they share several
common risk factors, including smoking, immobility,
and as our patient group – DM, it is not surprising that
a patient with CVD may have increased risk of venous
thromboembolism [33].
Previous studies reported metformin treatment was
associated with a decrease in vitamin B12 concentration
[34], which was present in 5.8% of the population [35]
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hyperhomocysterinemia. However the association be-
tween vitamin B12 deficiency and deep vein thrombosis
remained undetermined. Previous data have suggested
that there is no adequate evidence concerning the role
of metformin therapy and hyperhomocysteinemia. A
previous study from Thailand demonstrated s that
although metformin may have caused low vitamin B12
levels, there were no significant changes to homocyst-
eine levels [36]. Hoogeveen et al. further found that
metformin-exposed patients had only slightly higher
serum total homocysteine levels then control group
[37,38]. Furthermore, the dose–response relationship
between cumulative exposure to metformin and total
homocysteine level was not identified [38]. Besides med-
ications, other dietary factors such as fruit and vegetable
consumption in diabetic patients could also be strong
independent determinants of homocysteine levels [39].
Recent studies show that lowering homocysteine levels
does not decrease the risk for atherosclerosis or throm-
bosis [40,41]. This supports the theory that homocyst-
eine may just be an “innocent bystander” and not the
cause of these conditions. Therefore, large-scale preven-
tion studies identifying high-risk patients through gen-
etic tests, like C677T homozygous mutation targeting on
populations with low folate intake have not been per-
formed [42].
In addition, it has been reported that serum vitamin
B12 levels do not adequately assess tissue vitamin B12
stores [43]. Patients with type 2 diabetes may show nor-
mal extracellular vitamin B12, but disturbed intracellular
B12-dependent biochemical reactions. Metformin treat-
ment was associated with low serum vitamin B12 level,
while improved intracellular vitamin B12 metabolism
despite low serum vitamin B12 [44].
There are some limitations in our study. First, it is a
nonrandomized, pair-matched cohort study. The diagno-
ses of type 2 DM and DVT rely on ICD coding from
insurance claim database. The diagnosis of deep venous
thrombosis is confirmed by venography or lower limb
Doppler ultrasonography, while the arrangement and in-
terpretation of these image studies depend on clinician’s
judgment. Therefore the incidence of deep venous throm-
bosis may be underestimated. In addition, some personal
information, including smoking, immobilization or con-
current medication was not available in the administrative
data. Since smoking, immobility, or use of contraceptive
agents are well recognized risk factors of deep vein throm-
bosis [45]. Accurate assessment of the contributory and
confounding effect of these factors are not feasible. Be-
cause of the limitation of National Health Insurance Re-
search Database (NHIRD), we were unable to calculate
the propensity score as correction of comorbidities.
Individual biochemistry data was not available in thispopulation-based registry. Therefore, we cannot measure
patients’ coagulation and inflammation profiles, and the
relationship cannot be delineated. Despite these limita-
tions, this study was believed to give the first insight about
the effect of metformin on venous thromboembolism.
Conclusion
In conclusion, we identified that metformin therapy may
be associated with a protective effect in patients with
type 2 diabetes mellitus from deep vein thrombosis in a
large-scale population-based study. Further larger pro-
spective studies or meta-analysis are needed to confirm
our findings.
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